RO7812653 for Early Symptomatic Alzheimer's Disease

Overview

This Phase 1 trial investigates the safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7812653 following intrathecal administration in participants with early symptomatic Alzheimer's disease (eAD). The study is sponsored by Hoffmann-La Roche (also known as Roche) and represents an early-stage therapeutic approach targeting AD through direct CNS delivery.

RO7812653 is an investigational antibody-based therapeutic that targets a novel epitope in Alzheimer's disease pathology. The intrathecal delivery route represents an innovative approach to overcome the blood-brain barrier and achieve therapeutic concentrations in the CNS.

Trial Details

Overview

This Phase 1 trial investigates the safety, tolerability, pharmacokinetics, and pharmacodynamics of RO7812653 following intrathecal administration in participants with early symptomatic Alzheimer's disease (eAD). The study is sponsored by Hoffmann-La Roche (also known as Roche) and represents an early-stage therapeutic approach targeting AD through direct CNS delivery.

RO7812653 is an investigational antibody-based therapeutic that targets a novel epitope in Alzheimer's disease pathology. The intrathecal delivery route represents an innovative approach to overcome the blood-brain barrier and achieve therapeutic concentrations in the CNS.

Trial Details

| Field | Value |
|-------|-------|
| NCT ID | [NCT07234942](https://clinicaltrials.gov/study/NCT07234942) |
| Status | Recruiting |
| Phase | Phase 1 |
| Enrollment | 50 participants (estimated) |
| Sponsor | Hoffmann-La Roche |
| Design | Randomized, double-blind, placebo-controlled, parallel group |
| Masking | Quadruple (participant, care provider, investigator, outcomes assessor) |
| Start Date | January 27, 2026 |
| Primary Completion | April 19, 2028 (estimated) |
| Study Completion | March 5, 2030 (estimated) |
| Route | Intrathecal administration |

Trial Phases

| Phase | Description | Duration |
|-------|-------------|----------|
| Screening | Assessment of eligibility | 4 weeks |
| Treatment | Single ascending dose (SAD) or multiple ascending dose (MAD) | Up to 12 weeks |
| Follow-up | Safety and pharmacokinetic assessment | Up to 40 weeks |

Scientific Rationale

Limitations of Conventional AD Therapeutics

Current FDA-approved AD therapeutics face significant challenges:

• Large molecule therapeutics (antibodies) have limited CNS penetration
• <1% of peripherally administered monoclonal antibodies reach the brain
• Requires very high doses, increasing cost and systemic exposure

• Leptomeningeal/vasogenic edema (ARIA-E)
• Microhemorrhages (ARIA-H)
• Especially problematic with high-dose anti-amyloid antibodies

• Amyloid-targeted therapies show greatest benefit in early disease
• Need for earlier intervention or alternative mechanisms

Intrathecal Delivery Advantages

The intrathecal (IT) delivery approach offers several potential advantages[@intrathecal]:

| Advantage | Description |
|-----------|-------------|
| Bypasses BBB | Direct delivery to cerebrospinal fluid (CSF) |
| Lower dose required | ~10-100x lower doses than IV administration |
| Reduced systemic exposure | Lower risk of peripheral side effects |
| Direct CNS targeting | Higher drug concentrations at target site |
| Reduced ARIA risk | Lower systemic antibody exposure |

CSF Dynamics and Distribution

The intrathecal delivery of therapeutics must account for CSF dynamics[@cgfriver]:

Therapeutics delivered intrathecally must navigate these dynamics to achieve adequate brain parenchymal penetration.

Study Design

Intervention Arms

| Arm | Treatment | Route | Dose | Schedule |
|-----|-----------|-------|------|-----------|
| Active - Low Dose | RO7812653 | Intrathecal | Low | Single dose |
| Active - Mid Dose | RO7812653 | Intrathecal | Mid | Single dose |
| Active - High Dose | RO7812653 | Intrathecal | High | Single dose |
| Placebo | Saline solution | Intrathecal | N/A | Matching schedule |

Dose Escalation Strategy

The study uses a single ascending dose (SAD) design with sequential escalation:

Primary Endpoints

| Endpoint | Description | Assessment Timepoint |
|----------|-------------|---------------------|
| Safety | Incidence and severity of adverse events (AEs) | Up to ~40 weeks |
| Tolerability | Discontinuations due to AEs | Up to ~40 weeks |
| Suicidality | C-SSRS score change from baseline | Up to ~40 weeks |

Secondary Endpoints

| Endpoint | Description | Timepoint |
|----------|-------------|-----------|
| PK - Plasma | Plasma concentration of RO7812653 | Up to 40 weeks |
| PK - CSF | CSF concentration of RO7812653 | Up to 40 weeks |
| Immunogenicity | Anti-drug antibody (ADA) presence | Up to 40 weeks |

Exploratory Endpoints (if applicable)

• CSF biomarkers (Aβ, tau, NfL)
• Brain imaging (MRI, PET)
• Cognitive assessments

Eligibility Criteria

Inclusion Criteria

• Consistent with NIA-AA core clinical criteria

Key Exclusion Criteria

Additional Exclusion Criteria

• Contraindications to lumbar puncture
• Active infection or inflammatory condition
• Recent (within 2 years) malignancy
• Severe hearing or vision impairment
• Participation in other clinical trials within 30 days

Study Sites

Active Recruitment Sites

| Location | Institution | Status |
|----------|-------------|--------|
| Amsterdam, Netherlands | Brain Research Center Amsterdam | Recruiting |
| London, UK | National Hospital For Neurology and Neurosurgery | Recruiting |

Additional sites may be added during the trial.

RO7812653: Target and Mechanism

While specific details of RO7812653's molecular target are proprietary, the development of intrathecal antibody therapeutics for AD generally targets:

Potential Mechanisms

| Target Category | Description |
|-----------------|-------------|
| Amyloid-beta | Anti-Aβ antibodies to reduce plaque burden |
| Tau | Anti-tau antibodies to reduce neurofibrillary tangles |
| Novel targets | New therapeutic modalities (e.g., apoE, synaptic proteins) |

Why Intrathecal Delivery for Antibodies?

Biomarker Program

Pharmacodynamic Markers

| Biomarker | Sample | Purpose |
|-----------|--------|---------|
| Aβ40/Aβ42 | CSF | Amyloid plaque dynamics |
| Total tau | CSF | Neurodegeneration marker |
| Phosphorylated tau (p-tau) | CSF | Tau pathology |
| Neurofilament light chain (NfL) | CSF/Plasma | Axonal injury[@neurofilament] |

Safety Biomarkers

| Biomarker | Sample | Purpose |
|-----------|--------|---------|
| Red blood cells in CSF | CSF | Meningeal hemorrhage |
| Protein in CSF | CSF | Infection/inflammation |
| Glucose in CSF | CSF | Infection/metabolism |

Competitive Landscape

Intrathecal AD Therapeutics

| Drug | Company | Target | Phase | Status |
|------|---------|--------|-------|--------|
| RO7812653 | Roche | TBD | Phase 1 | Recruiting |
| Lecanemab (LEQEMBI) | Eisai/Biogen | Aβ protofibrils | Approved (IV) | Launched |
| Donanemab | Eli Lilly | Aβ plaque | Phase 3 (IV) | Filing |
| Gantenerumab | Roche | Aβ plaque | Phase 3 (IV) | Discontinued |
| Crenezumab | Roche | Aβ oligomers | Phase 2 | Discontinued |

Novel Delivery Approaches in AD

| Approach | Description | Development Stage |
|----------|-------------|------------------|
| Intrathecal antibodies | Direct CNS delivery | Phase 1-2 |
| Intranasal delivery | Nose-to-brain pathway | Preclinical-Phase 1 |
| Focused ultrasound | BBB opening for IV delivery | Phase 2 |
| AAV gene therapy | CNS expression of therapeutic proteins | Preclinical |

Safety Considerations

Intrathecal Delivery Risks

| Risk | Description | Mitigation |
|------|-------------|------------|
| Spinal headache | CSF leak causing positional headache | Bed rest post-procedure |
| Infection | Meningitis risk | Sterile technique |
| Bleeding | Spinal hematoma | Pre-procedure coagulation check |
| Nerve injury | Transient neurological symptoms | Expert administration |
| Brain herniation | Rare complication with mass effect | MRI screening |

Expected Adverse Events (based on similar intrathecal therapeutics)

| Event | Expected Frequency | Management |
|-------|-------------------|------------|
| Post-LP headache | 10-20% | Hydration, caffeine |
| Back pain | 5-10% | Analgesics |
| Nausea | 3-5% | Anti-emetics |
| CSF pleocytosis | Rare | Monitoring |
| Infection | Very rare | Sterile technique |

Clinical Significance

Why This Trial Matters

Potential Impact

If Successful

• Would validate intrathecal delivery as viable AD treatment route
• Could accelerate development of additional intrathecal therapeutics
• May enable combination therapy approaches
• Could expand treatment options for early AD patients

If Unsuccessful

• Would identify limitations of intrathecal delivery
• May inform optimal dosing strategies
• Would contribute to understanding of CNS antibody pharmacokinetics
• Would guide development of alternative delivery methods

Challenges and Considerations

Current Status (March 2026)

The trial is actively recruiting as of March 2026. The trial initiated in January 2026 and is expected to complete primary endpoints by April 2028, with full study completion in March 2030.

Milestones:

• January 2026: First patient dosed
• Q2 2026: Initial safety data from first cohort
• 2027-2028: Dose escalation and expansion cohorts
• 2028-2030: Long-term follow-up

Cross-References

• [Alzheimer's Disease](/diseases/alzheimers-disease) — Disease overview
• [Alzheimer's Disease Clinical Trials](/clinical-trials/drug-pipeline) — Other AD trials
• [Intrathecal Drug Delivery](/mechanisms/intrathecal-drug-delivery) — CNS delivery mechanisms
• [Amyloid-Targeting Therapies](/therapeutics/anti-amyloid-therapeutics) — Drug class
• [Blood-Brain Barrier](/mechanisms/blood-brain-barrier) — Delivery challenges

See Also

• [Biogen](/companies/biogen) — Company page
• [Roche](/companies/roche) — Company page
• [Antibody Therapeutics in AD](/therapeutics/anti-amyloid-therapeutics)
• [Phase 1 Trial Design](/mechanisms/clinical-trial-design)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving RO7812653 for Early Symptomatic Alzheimer's Disease discovered through SciDEX knowledge graph analysis: